Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2011-03-15
2011-03-15
Kishore, Gollamudi S (Department: 1612)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C424S649000, C514S274000, C514S449000, C514S492000
Reexamination Certificate
active
07906554
ABSTRACT:
This invention relates to combination therapies involving anticancer chemotherapeutic agents and isoflavones or analogues thereof. The invention further relates to compounds, methods and therapeutic uses involving, containing, comprising, including and/or for preparing platinum-isoflavonoid complexes suitable for use in the combination therapies of the invention.
REFERENCES:
patent: 6380405 (2002-04-01), Ekwuribe et al.
patent: 2337256 (2000-01-01), None
patent: 1312712 (2001-09-01), None
patent: 267155 (1988-05-01), None
patent: 5-070348 (1993-03-01), None
patent: WO 80/02098 (1980-10-01), None
patent: 98/08503 (1998-03-01), None
patent: WO98/08503 (1998-03-01), None
patent: WO 98/17662 (1998-04-01), None
patent: WO 99/49862 (1999-10-01), None
patent: 00/03707 (2000-01-01), None
patent: WO 00/66576 (2000-11-01), None
patent: 01/17986 (2001-03-01), None
patent: WO 02/02548 (2002-01-01), None
patent: 03/086386 (2003-10-01), None
Khoshyomn, et al, Synergistic Action of Genistein and Cisplatin on Growth Inhibition and Cytotoxicity of Human Medulloblastoma Cells,Pediatric Neurosurgery; Sep. 2000; 33, 3; p. 123-131.
Suggitt and Bibby, Clinical Cancer Research, 2005, vol. 11, 971-981.
STN File Medline, abstract accession No. 2003459262 & Tamura S. et al., Pigment Cell Research, (Oct. 2003) 16 (5) 470-6, “Genistein enhances the ciplatin-induced inhibitions of cell growth and apoptosis in human malignant melanoma cells”.
STN File Biosis, abstract accession No. 2003:368481 & Mansour A. et al., Blood (Nov. 16, 2002) vol. 100, No. 11, pp. Abstract No. 4997, “Enhancement of chemotherapeutic efficacy by combining agents that block IL-10 in CIL cell lines”.
STN File Medline, abstract accession No. 2002151803 & S. Giacomelli et al., Life Sciences (Feb. 8, 2002), pp. 1447-1459, “Silybin and its bioavailable phospholipids complex (IdB 1016) potentiate in vitro and in vivo in the activity of cisplatin”.
STN File Medline, abstract accession No. 2000404390 & Caltagirone S. et al, International Journal of Cancer (Aug. 15, 2000), 87 (4), pp. 595-600, “Flavanoids apigenin and quercetin inhibit melanoma growth and metastatic potential”.
STN File Medline, abstract accession No. 96273517 & Scambia G. et al, European Journal of Cancer (May 1996), 32A(5), pp. 877-882, “Antiproliferative effect of silybin on gynaecological malignancies: synergism with cisplatin and doxorubicin”.
STN File Medline, abstract accession No. 91191699 & Waud W. R. et al, Cancer Chemotherapy and Pharmacology (1991), 27(6), pp. 456-463, “Antitumor drug cross-resistance in vivo in a cisplatin-resistant murine P388 leukemia”.
STN File Medline, abstract accession No. 91107211 & Neelam S. S. et al, Investigational New Drugs (Aug. 1990), 8 (3), pp. 263-268, “Combination of flavone acetic acid (FAA) with adriamycin, cisplatinum and difluoromethylornithine (DFMO) in vitro against human colon cancer cells”.
STN File Medline, abstract accession No. 92032982 & Scambia G. et al, Anti-Cancer Drugs (Oct. 1990), 1 (1), pp. 45-48, “Synergistic antiproliferative activity of quercetin and cisplatin on ovarian cancer cell growth”.
STN File CA, abstract No. 119:131038 & De Vincenzo R. et al, Acta Medica Romana (1992), 30 (1-2), pp. 126-132, “Flavanoids and negative control of cell proliferation in ovarian tumors”.
Zyner E. et al, Acta Poloniae Pharmaceutica Drug Research, 1999, 56(2), pp. 159-167, “Platinum (II) and palladium (II) N, O-chelates with substituted flavanone containing ligands”.
Zyner E. et al, Pharmazie, 1999, 54 (12), pp. 945-946, “Pt (II) and Pd (II) complexes of 3-aminoflavone: in vitro and in vivo evaluation”.
Lei W. et al, Anticancer Research, 1999, vol. 19, pp. 221-228, “Enhancement of chemosensitivity and programmed cell death by tyrosine kinase inhibitors correlates with EGFR expression in non-small cell lung cancer cells”.
Kang B-J et al, Natural Product Sciences, 2000, 6(4), pp. 165-169, “Scientific analysis of formulation theory of Chungpesagan-tang; in vitro cytotoxicity of cisplatin combined with Chungpesagan-tang”.
Sepulveda-Boza, S et al, “The Preparation of New Isoflavones”, Synthetic Communications (2001) vol. 31 No. 12 pp. 1933-1940.
O'Neil, M J. et al, “Inducible Isoflavonoids from the Lima Bean, Phaseolus lunatus”, Phytochemistry (1986) vol. 25, No. 6 pp. 1315-1322.
Wolfbeis, O S et al, “The Absorption and Fluorescence of Isoflavones and the Effect of Shift Regents”, Z. Naturforsch (1984) 39b pp. 238-243.
Arora, S K et al, “The Synthesis of Tlatlancuayin”, Tetrahedron (1962) vol. 18 pp. 559-565.
STN Chemical Abstract Accession No. 135: 355315 & Chemical and Pharmaceutical Bulletin (2001), 49 (9), 1229-1231.
STN Chemical Abstract Accession No. 135:121648 & Journal of Agricultural and Food Chemistry (2001), 49 (6) 3024-3033.
STN Chemical Abstract Accession No. 124:341448 & Archives of Microbiology (1995), 164 (6), 428-34.
STN Chemical Abstract Accession No. 124:316797 & Chemical and Pharmaceutical Bulletin (1996), 44 (3), 486-91.
STN Chemical Abstract Accession No. 124: 140985 & Tennen Yuki Kagobutsu Toronkai Koen Yoshishu (1995), 37th, 493-8.
STN Chemical Abstract Accession No. 115:68424 & Phytochemistry (1991), 30 (4), 1281-4.
STN Chemical Abstract Accession No. 114:41246 & Angewandte Botanik (1990), 64 (1-2), 175-90.
STN Chemical Abstract Accession No. 112:69573 & International Journal of Tissue Reactions (1989), 11 (3), 107-12.
STN Chemical Abstract Accession No. 102:59329 & Phytochemistry (Elsevier) (1984), 23 (11), 2703-4.
STN Chemical Abstract Accession No. 102:59220 & Phytochemistry (Elsevier) (1984), 23 (6), 1342-3).
STN Chemical Abstract Accession No. 97:109739 & J. Chem. Soc., Perkin Trans. 1 (1982), (6), 1389-94.
STN Chemical Abstract Accession No. 95:111690 & Phytochemistry (1981), 20 (4), 799-801.
STN Chemical Abstract Accession No. 82:97918 & J. Inst. Chem., Calcutta (1974), 46, Pt. 3, 61-5.
STN Chemical Abstract Accession No. 76:140428 & J. Inst. Chem., Calcutta (1971), 43 (6), 234-40.
STN Chemical Abstrac Accession No. 70:57577 Indian J. Chem. (1968), 6 (9), 481-4.
STN Chemical Abstract Accession No. 63:54547 & Bull. Chem. Soc. Japan (1965), 38 (6), 887-93.
STN Chemical Abstract Accession No. 61:61569 & Periodica Polytech. (1963), 7 (4), 241-58.
STN Chemical Abstract Accession No. 126:139728 (see CAS RN 116718-84-4) & Atherosclerosis (1997), 128 (1), 59-66.
Jha, H C et al, “Carbon-13 Chemical Shift Assignments of Chromones and Isoflavones”, Can. J. Chem. (1980) vol. 58 No. 12 pp. 1211-1219.
STN Chemical Abstracts Accession No. 128:164027 & Antioxidants in Health and Disease (1998), 7 (Flavanoids in Health and Disease) pp. 295-302.
STN Chemical Abstracts Accession No. 117:124019 & Biochemical Pharmacology (1992) vol. 44 (1), pp. 157-162.
Abstract XP002541865, “Phenoxodiol enters phase II leukemia trial”, DailyDrugNews.com (Daily Essentials), Sep. 26, 2002.
Andreas I. Constantinou, et al., “Phenoxodiol (2H-1-Benzopyran-7-0,1,3-(4-hydroxyphenyl)), A Novel Isoflavone Derivative, Inhibits DNA Topoisomerase II by Stabilizing the Cleavable Complex”, Anticancer Research, vol. 22, No. 5, pp. 2581-2586, Sep. 2002.
Tito Fojo, et al., “Taxol and other microtubule-interactive agents”, Current Opinion in Oncologic, Endocrine and Metabolic Investigational Drugs, vol. 2, No. 3, pp. 293-304, Jan. 1, 2000.
Dirk Th. Sleijfer, et al., “Cisplatin: a review of clinical applications and renal toxicity”, Pharmaceutish Weekblad Scientific Edition, vol. 7, No. 6, pp. 237-244, Dec. 13, 1985.
Antona J. Wagstaff, et al., “Carboplatin. A preliminary review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in the treatment of cancer”, Drugs, vol. 37
Kishore Gollamudi S
Novogen Research Pty Ltd
Packard Benjamin
Sughrue & Mion, PLLC
LandOfFree
Combination chemotherapy compositions and methods does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Combination chemotherapy compositions and methods, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Combination chemotherapy compositions and methods will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2780561